HOME >> MEDICINE >> NEWS
Brief, high-dose steroid treatment offers extended relief to giant cell arteritis patients

ATLANTA -- A new study offers both hope and a practical treatment option for patients with giant cell arteritis (GCA). Researchers from Emory University and the Mayo Clinic have found that by treating newly diagnosed GCA patients with just three days of a high-dose intravenous steroid, patients relapsed less in the following year and were able to significantly taper off usage of an oral steroid. The study is published in the October issue of the journal Arthritis & Rheumatism.

Giant cell arteritis is characterized by inflammation of arteries, primarily in the head, and affects 20 out of every 100,000 people. GCA inflammation may lead to swelling and headaches, or, as it progresses, vision loss, strokes and aortic aneurysms. While past research has shown a genetic link to the disease, which primarily affects Caucasian women over the age of 50, there is no known cause or cure.

For the last 40 years, physicians have been able to treat and reverse some symptoms of GCA by prescribing prednisone, to be taken daily over a year or more. "Patients improve promptly and reliably, within days of when we treat them," says Cornelia M. Weyand, MD, PhD, co-director of the Kathleen B. and Mason I. Lowance Center for Human Immunology at Emory University and an author of the paper. "The problem is that patients have to take prednisone for a long time and in high doses, and they are at risk of developing side effects." Common side effects include hypertension, diabetes and osteoporosis.

While scientists have attempted to develop new drugs that would be more effective and have fewer side effects, their results have been unsuccessful. "We and others tried to look into other types of treatments that could help with this disease," says Jrg Goronzy, MD, PhD, senior author of the paper, and co-director of the Lowance Center.

"Even the modern and effective immunosuppressants do not improve the situation with these patients," says Dr. Weyan
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
2-Oct-2006


Page: 1 2

Related medicine news :

1. Study examines characteristics of female high school students who report steroid use
2. Female teen steroid use not limited to athletes
3. Bronchial thermoplasty may allow severe asthma patients to wean off oral corticosteroids
4. Inhaled steroids may not be enough for some children with asthma
5. Nonsteroidal anti-inflammatory drugs use associated with higher gastrointestinal complications
6. Short-term topical corticosteroid use may offer relief for patients with acute form of psoriasis
7. Pre-clinical study suggests how steroid can reverse post-traumatic stress
8. Inhaled corticosteroids reduce death in patients with COPD
9. Non-steroidal anti-inflammatory drugs (NSAIDs) and congenital anomalies
10. National trial gives unprecedented support for steroid withdrawal in kidney transplants
11. New study adds weight to argument for steroid injections in patients with hip osteoarthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
Cached News: